New Issue: Catalyst raises $20.1 million in IPO of upsized 3.35 million shares at $6 each

By Ronda Fears

Memphis, Nov. 8 - Catalyst Pharmaceuticals Partners, Inc. raised $20.1 million from its initial public offering of 3.35 million shares, boosted from 3 million, at $6 each - pat with price talk lowered from original guidance for $11 to $13, via bookrunner First Albany Capital, Inc.

Coral Gables, Fla.-based Catalyst - focused on prescription drugs to treat addiction, plans to use proceeds to fund phase 2 and phase 3 trials of CPP-109 for cocaine addiction, to file a New Drug Application for CPP-109 and for further studies of CPP-109 for methamphetamine and nicotine addiction.

Issuer:	Catalyst Pharmaceuticals Partners, Inc.
Issue:	Initial public offering
Gross proceeds:	$20.1 million
Net proceeds:	$18.7 million
Shares:	3.35 million, up from 3 million
Greenshoe:	502,500 shares, up from 450,000
Price:	$6 per share
Price talk:	Revised: $6 per share
	Original: $11 to $13 per share
Bookrunner:	First Albany Capital, Inc.
Co-manager:	Stifel, Nicolaus & Co., Inc.
Pricing date:	Nov. 7
Settlement date:	Nov. 13
Stock symbol:	Nasdaq: CPRX

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.